Open AccessPharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan
Author(s) -
Janelle M. Hoskins,
Gary L. Rosner,
Mark J. Ratain,
Howard L. McLeod,
Federico Innocenti
Publication year - 2009
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs.09.35
Subject(s) - irinotecan , pharmacodynamics , medicine , neutropenia , pharmacology , oncology , cancer , pharmacokinetics , chemotherapy , colorectal cancer
A recent study found that variation in camptothecin pharmacodynamic genes (TOP1, PARP1, TDP1 and XRCC1) correlated with efficacy and risk of neutropenia in irinotecan-treated cancer patients (median dose: 180 mg/m2), which suggests that these genes might predict outcomes to irinotecan-based therapies. The present study was conducted to evaluate previous gene associations using an independent sample of patients receiving irinotecan.